论文部分内容阅读
75例初诊T2DM患者,按单、双日随机分为两组,对照组瑞格列奈1~3mg及二甲双胍0.25~0.5,每日各三次口服;强化组给予甘舒霖R(三餐前30分钟),甘舒霖N(睡前)皮下注射。4周后观察治疗前后空腹血糖(FBG)、餐后2小时血糖(2HBG)、糖化血红蛋白A1c(HbA1c)、胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)、血糖达标时间等。结果:两组病人治疗后,上述指标均有明显下降,强化组下降更明显分别为(15.8±3.2)mmol/Lvs(5.9±0.5)mmol/L,(20.2±3.8)mmol/L(7.5±0.5)mmol/L,(10.4±1.36)%vs(6.96±0.74)%,均P<0.01,(3.49±0.82)vs(5.32±2.20),(2.20±0.81)vs(1.02±0.41),均P<0.05。结论:甘舒霖强化治疗初诊T2DM,能明显增强胰岛β细胞的功能,减轻胰岛素抵抗,使患者血糖良好控制。
75 cases of newly diagnosed T2DM patients were randomly divided into two groups according to the single and double days. The control group was treated with repaglinide 1 ~ 3mg and metformin 0.25 ~ 0.5 orally three times a day orally. The intensive group was given Gan Shulin R (30 minutes before meals) , Gansu Lin N (bedtime) subcutaneous injection. After 4 weeks, FBG, 2HBG, HbA1c, HOMA-β, HOMA-IR, Time and so on. Results: After treatment, the above indexes were significantly decreased in both groups, and were significantly decreased in the intensive group (15.8 ± 3.2) mmol / L vs (5.9 ± 0.5) mmol / L and (20.2 ± 3.8) mmol / L (P <0.01), (3.49 ± 0.82) vs (5.32 ± 2.20), (2.20 ± 0.81) vs (1.02 ± 0.41) vs (10.4 ± 1.36)% vs (6.96 ± 0.74)% P <0.05. Conclusion: Gan Shu-lin treatment of newly diagnosed T2DM, can significantly enhance the function of pancreatic β-cells, reduce insulin resistance, so that patients with good blood sugar control.